Drug intelligence / Profile preview

DN24-02

Development stage: Unknown
Lead developer: Dendreon
Modality: Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

DN24-02 is an investigational autologous cellular immunotherapy designed to stimulate an immune response against the HER2/neu antigen. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen-presenting cells (APCs), which are cultured ex vivo with BA7072, a recombinant HER2-derived antigen. The therapy aims to induce a targeted immune response in patients with HER2-positive cancers, particularly high-risk urothelial carcinoma. DN24-02 is based on the same manufacturing platform as sipuleucel-T and was developed by Dendreon[1][3][7][8].

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on DN24-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DN24-02.

Explore the full profile